SCHEMBL1746767

SCHEMBL1746767

CCCN(Cc1ccc(CO)cc1)c1nc2c(s1)CCc1ccccc1-2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
ADORA1 P30542 1/20 0.43
POLB P06746 2/20 0.42
ATP4A P20648 1/20 0.41
ATP4B P51164 1/20 0.41
ALOX5 P09917 1/20 0.41
AGTR1 P30556 4/20 0.41
AGTR2 P50052 4/20 0.41
KMT2A Q03164 4/20 0.39
XIAP P98170 1/20 0.39
MEN1 O00255 3/20 0.39
HKDC1 Q2TB90 1/20 0.39
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745417 0.85 KDM4E (0.50) ALDH1A1KDM4EHPGDADORA1POLB
SCHEMBL1745335 0.78 PPARD (0.41) ALDH1A1KDM4EHPGDPOLBALOX5
SCHEMBL1744793 0.75 AGTR1 (0.46) ALDH1A1HPGDPOLBATP4AATP4B
SCHEMBL1745637 0.71 AGTR1 (0.46) AGTR1AGTR2KMT2ANPC1RAB9A
SCHEMBL20653276 0.68 ADORA1 (0.56) ALDH1A1KDM4EHPGDADORA1POLB
SCHEMBL1744940 0.66 KMT2A (0.53) ALDH1A1HPGDATP4AATP4BAGTR1
SCHEMBL10076399 0.65 ADORA1 (0.64) ALDH1A1KDM4EHPGDADORA1POLB
SCHEMBL1744879 0.65 POLB (0.61) ALDH1A1KDM4EHPGDADORA1POLB
SCHEMBL27834222 0.63 POLB (0.58) ALDH1A1KDM4EHPGDADORA1POLB
SCHEMBL1745165 0.62 ADORA1 (0.97) ALDH1A1KDM4EHPGDADORA1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR ALDH1A1 4258/4885KDM4E 3200/4885HPGD 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.